Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on The Cash Flow Compounder’s Substack. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $129.61 as of March 6th. TMDX’s trailing and forward P/E were 26.61 and 56.18 respectively according to Yahoo Finance.
Africa Studio/Shutterstock.com
TransMedics Group (TMDX) is a medical technology company revolutionizing organ transplantation with its patented Organ Care System, which preserves organs in warm, oxygenated, nutrient-rich blood, allowing longer transport times and pre-transplant function assessment. This innovation addresses the persistent organ shortage, expanding the usable donor pool. Leveraging its success, TMDX has developed the National Organ Care System Program, a full-service solution that combines Organ Care System technology, specialized staff, and logistics—including a fleet of 21 company-owned jets—to manage organ retrieval and transport nationwide.
Revenue is generated on a usage-based model, with TMDX earning from device sales, consumables, and National Organ Care System Programservices across heart, lung, and liver transplants, covering 91% of U.S. Organ Care Systemcases. The company’s patented technology, regulatory barriers, and high switching costs create a wide economic moat, while its repeat-use model and life-saving service foster customer stickiness. Financially, TMDX turned profitable in early 2024, with net margins expanding to 16.2% in the last twelve months, and projects a 22.6% revenue annual growth rate through 2028.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains
Risks include regulatory dependence, potential disruption from xenotransplantation or synthetic organs, and the complexity of its asset-heavy logistics operation. However, the combination of robust growth prospects, a dominant market position in normothermic perfusion, and the essential nature of its services makes TransMedics an attractive investment.
For long-term investors, the company offers both structural growth and a strong competitive position, positioning TMDX to capitalize on secular trends in organ transplantation while maintaining resilience against economic cycles. Its integrated technology and logistics model suggest substantial upside potential as adoption continues domestically and expands into high-growth international markets.
Previously, we covered a bullish thesis on TransMedics Group, Inc. by Oliver in May 2025, which highlighted the company’s transformative Organ Care System, National Organ Care SystemProgram, rapid revenue growth, expanding margins, and regulatory moat. TransMedics Group, Inc’s stock price has appreciated by approximately 35.27% since our coverage. The Cash Flow Compounder shares a similar view but emphasizes updated profitability, a clear 2028 revenue CAGR outlook, and long-term structural growth potential.
TransMedics Group, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held TMDX at the end of the fourth quarter which was 34 in the previous quarter. While we acknowledge the risk and potential of TMDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
